stockrow
Saturday 7 November 2026
Export KLRA’s income statement to Excel — free account
Kailera Therapeutics, Inc.
KLRA Healthcare Biotechnology
- EPS
- +100.0%
- Free cash flow
- −326.0%
Quarter to September 2026, against a year earlier
12.97
0.80
+6.57%
Follow KLRA
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Current Ratio |
+4 more quarters Free account |
12.01 | 9.67 | 11.11 | 21.84 |
Net Debt/EBITDA |
8.15 | 6.14 | 7.56 | 8.49 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.74 | 0.87 | 0.70 | 1.40 | |
Capex/Depreciation |
(13.48) | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(238,625.00) | (3,162.50) | (0.76) | (1.03) | |
Cash per Share |
2,730,280.00 | 24,035.83 | 8.97 | 6.95 | |
Shareholders Equity per Share |
3,179,530.00 | 25,938.70 | 10.94 | 7.95 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3,179,530.00 | 25,938.70 | 10.94 | 7.95 | |
Free Cash Flow |
(47.72) | (68.31) | (77.53) | (133.67) | |
Working Capital |
511.13 | 475.48 | 845.52 | 877.64 | |
Capital Expenditures |
(1.64) | — | — | — | |
Net Current Asset Value |
501.15 | 465.84 | 836.22 | 868.69 | |
| Other line items | |||||
Quick Ratio |
11.77 | 9.47 | 10.96 | 21.40 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(230,400.00) | (3,162.50) | (0.76) | (1.03) | |
Capex per Share |
(8,225.00) | 0.00 | 0.00 | 0.00 | |
Average Payables |
— | — | — | 5.72 | |
Average Assets |
— | 401.60 | 605.71 | 630.31 | |
Average Common Equity |
— | — | — | 406.17 | |
Capex to Sales |
0.00 | — | — | — |
Columns are period end dates · fundamentals updated 6 Nov 2026